SUMMARY Plasma fibrinolytic activity and plasma inhibitory activity against urokinase and tissue activator were measured in primigravidae with moderate or severe pre-eclampsia and in gestationmatched primigravidae with uncomplicated pregnancy. The mean levels of fibrinolytic activity and inhibitory activity against urokinase and tissue activator did not differ significantly between the pre-eclampsia and uncomplicated pregnancy groups. The pattern of inhibitory fractions of plasminogen-depleted plasma from pre-eclamptic and uncomplicated primigravidae after gel filtration on Sephadex G-100 was similar.
The long-standing observation that widespread fibrin deposition is common in patients with severe preeclampsia and eclampsia has led to the suggestion that there is an abnormality in the mechanism for the deposition or removal of fibrin in toxaemia of pregnancy. Some have championed the view that fibrin persistence through failure of the fibrinolytic system might be aetiologically important in preeclampsia.
Studies on the fibrinolytic system in pre-eclampsia have provided conflicting results. While Bonnar and colleagues' reported that plasma fibrinolytic activity is lower in women with severe pre-eclampsia, others have observed no alteration in fibrinolytic activity in patients with pre-eclampsia or eclampsia.24 A diminished sensitivity to urokinase-induced fibrinolysis was found by Bonnar et all and Howie et al.3 We report a study comparing plasma fibrinolytic activity and, using a new technique, plasma inhibition of plasminogen activators in primigravidae with pre-eclampsia and those with uncomplicated pregnancy.
Material and methods
Plasma Blood was withdrawn from an antecubital vein and mixed with 1/9 volume of 3-8% sodium citrate. The plasma was separated by centrifugation at 2500g for 10 min and used immediately or stored at -20°C until required. Plasminogen-free plasma was prepared by mixing one part plasma with two parts of lysine-Sepharose (AB Pharmacia, Uppsala, Sweden The euglobulin fraction of plasma does not include inhibitors of the fibrinolytic system except for Cl inactivator, and the activity of euglobulin precipitates on fibrin plates is primarily a measure of plasminogen activator. In a separate study we found that the mean levels of a2-antiplasmin, the major plasma inhibitor of plasmin, and the other plasma protease inhibitors (a2-macroglobulin, a1-antitrypsin, Ci inactivator and antithrombin III) were not significantly different between women with uncomplicated pregnancy and those with preeclampsia. 10 The existence and characterisation of inhibitors of plasma activators distinct from the known protease inhibitors has not been established, and the measurement of plasma inhibition of activators has been unsatisfactory. The technique used in this study involves the removal of plasminogen from the test plasma to obviate the problem of plasmin formation on the addition of activator to plasma. Using this method we have been able to detect inhibition of both tissue activator and urokinase by plasma. The level of inhibition against both activators, however, did not differ between the women with uncomplicated pregnancy and those with pre-eclampsia, although the sample was small. The pattern of inhibition against tissue activator and urokinase seen in gel filtered plasminogen-free plasma from healthy, non-pregnant adults" and pregnant women9 was also seen in plasma from women with pre-eclampsia. The technique is not quantitative, but the peaks of inhibition appeared to be similar in magnitude in the plasma fractions from the normal and pre-eclamptic women.
Overall the results of this study provide no evidence to support the hypothesis that an abnormality in the fibrinolytic enzyme system is related to preeclampsia.
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